AIDS News and Research

RSS

University of Texas scientist creates promising HIV vaccine candidate

The Abzyme Research Foundation announces today that Dr. Sudhir Paul, a scientist at University of Texas Houston Medical School, has identified an important immunological deficiency in HIV-infected patients and has created a promising HIV vaccine candidate that rectifies the deficiency. The discoveries were presented on July 19th and 20th, 2010 at the XVII International AIDS Society Conference in Vienna, Austria.

21 Jul 2010

Opinions: AIDS vaccine and cure; China's role in the Global Fund; Child marriage prevention act; Gorbachev on safe water

A Globe and Mail editorial discusses the importance of "the quest for an AIDS vaccine and the search for a cure," stating that "it is simply not possible to 'treat' our way out of this disease." The authors write that "for every person who receives treatment - which must continue over their entire lifetime - about three new people become infected."

21 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

HIV – Rising menace

Nevirapine is considered to be an effective drug that can prevent HIV infection in babies born to mothers with HIV. However a new study shows that only about half of babies born to mothers with HIV receive the drug. The study appeared in the July 21 HIV/AIDS themed issue of the Journal of the American Medical Association.

20 Jul 2010

TeleHealth Services announces dates, keynote speakers for TIGRCon10

TeleHealth Services, the nation's leading provider of healthcare grade televisions and on-demand interactive patient education solutions, announced today the dates and keynote speakers for TIGRCon10, the company's annual patient education user conference. The conference, which will be focused on learning to deliver an optimal patient recovery process and improve clinical workflow, will enable hospital leadership and staff members to share best practices, discuss the role of technology in shaping the patient experience, gain new ideas and perspectives through a power user panel, and network with colleagues in the industry.

20 Jul 2010

First Edition: July 20, 2010

Today's headlines reflect more analysis and debate regarding continuing health reform implementation efforts.

20 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

The use of routine HIV screening in a hospital emergency department, which patients had the option to decline, was associated with only a modest increase in the number of patients with newly diagnosed HIV infection, compared to physician-directed diagnostic rapid HIV testing, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

WHO announces new approaches to HIV prevention and treatment among children

Efforts worldwide on access to treatment for children with HIV have reached a new milestone, with 355 000 children receiving life-saving HIV treatment at the end of 2009, compared to 276 000 at the end of 2008; but many more lives could be saved if more infants started on medication earlier according to new recommendations from the World Health Organization (WHO).

20 Jul 2010

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

In the ongoing battle to prevent mother-to-child transmission of human immunodeficiency virus (HIV), not all weapons are being used: Only about half of HIV-exposed infants in some African countries received a minimal dose of the prevention drug nevirapine, say researchers at the University of Alabama at Birmingham.

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

PSI to release evidence supporting quality scale-up of male circumcision

Following the remarks on male circumcision made today by former President Bill Clinton and philanthropist Bill Gates, PSI will release the results of a groundbreaking study on a new model of efficiency that will allow for quality and cost-effective scale-up of male circumcision.

20 Jul 2010

Bill Gates calls for renewed focus on reducing new HIV infections

Speaking to the 18th International AIDS Conference today, Bill Gates called on all countries to keep up the fight against HIV/AIDS, saying the world has an historic opportunity to "change the face of AIDS." Mr. Gates said current efforts to treat people with HIV are saving millions of lives, and urged a renewed focus on reducing annual new HIV infections up to 90% by 2031, the year that will mark 50 years of the AIDS epidemic.

20 Jul 2010

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.

20 Jul 2010

Education campaign positively impacts attitudes, behaviour of young people towards HIV/AIDS

INTERNATIONAL AIDS CONFERENCE 2010 -- MTV, the U.S. President's Emergency Plan for AIDS Relief and UNICEF today unveiled at INTERNATIONAL AIDS CONFERENCE 2010, new research on its Staying Alive Ignite Campaign at, which found that creating compelling pro-social entertainment for young people can positively impact attitudes and behaviour towards HIV and AIDS.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

Scientists find major shortcomings in assessing CVD risk in HIV patients

At the same time that medical science has nearly eliminated AIDS deaths in patients treated for human immunodeficiency virus, two international meetings of HIV/AIDS scientists and patient advocates find major shortcomings in the design and analysis of studies used to assess cardiovascular disease risk in people with HIV with significant implications for improving medical care.

20 Jul 2010

AHF calls upon US to honor commitment to PEPFAR

Doctors and AIDS advocates from AIDS Healthcare Foundation (AHF), which provides AIDS medical care to more than 138,000 individuals in 23 countries worldwide, will host a press conference at the International AIDS Conference in Vienna on Monday, July 19th at 12 noon (Media Center, Room PCR #3) to reiterate their call on the United States to honor the its landmark commitment to PEPFAR (the President's Emergency Plan for AIDS Relief), the successful US global AIDS program.

20 Jul 2010

WHO advises earlier treatment for people with HIV

An estimated 5.2 million people were receiving life-saving HIV treatment at the end of 2009, according to the latest update from the WHO. WHO estimates that 1.2 million people started treatment in 2009, bringing the total number of people receiving treatment to 5.2 million, compared to 4 million at the end of 2008.

20 Jul 2010

AIDS News and Research

University of Texas scientist creates promising HIV vaccine candidate

Opinions: AIDS vaccine and cure; China's role in the Global Fund; Child marriage prevention act; Gorbachev on safe water

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

HIV – Rising menace

TeleHealth Services announces dates, keynote speakers for TIGRCon10

First Edition: July 20, 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Nontargeted opt-out screening associated with newly identified HIV-infected patients: Study

WHO announces new approaches to HIV prevention and treatment among children

Only 51% of HIV-exposed infants received minimal dose of prevention drug nevirapine: Study

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

PSI to release evidence supporting quality scale-up of male circumcision

Bill Gates calls for renewed focus on reducing new HIV infections

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Education campaign positively impacts attitudes, behaviour of young people towards HIV/AIDS

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Scientists find major shortcomings in assessing CVD risk in HIV patients

AHF calls upon US to honor commitment to PEPFAR

WHO advises earlier treatment for people with HIV

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News